Study guide
6.3 Financial Agreements, Contracts, and Insurance
SOCRA CCRP Certified Clinical Research Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Ethical Codes & Guidelines
1.1 The Nuremberg Code (1947) 1.2 The Declaration of Helsinki (1964) 1.3 The Belmont Report (1979)
2 Chapter 2: U.S. Federal Regulatory Framework
2.1 FDA vs. HHS Governance & 45 CFR Part 46 2.2 Electronic Records & Signatures (21 CFR Part 11) 2.3 Financial Disclosure Requirements (21 CFR Part 54)
3 Chapter 3: Institutional Review Boards & Informed Consent
3.1 IRB Structure, Roles, and Responsibilities (21 CFR Part 56) 3.2 Informed Consent Core Elements & Process (21 CFR Part 50) 3.3 Informed Consent in Special Circumstances & Exceptions 3.4 Vulnerable Populations & Additional Safeguards (Subparts B, C, D)
4 Chapter 4: Protocol & Essential Documentation
4.1 Protocol Design and Investigator's Brochure (ICH E6 Section 6 & 7) 4.2 Essential Documents Checklist (ICH E6 Section 8) 4.3 Case Report Forms (CRFs) & Source Documentation
5 Chapter 5: Investigational Applications (IND & IDE)
5.1 Investigational New Drug (IND) Applications (21 CFR Part 312) 5.2 Investigational Device Exemptions (IDE) & Device Classification (21 CFR Part 812) 5.3 Expanded Access & Humanitarian Device Exemptions (HDE)
6 Chapter 6: Investigator & Sponsor Responsibilities
6.1 Investigator Responsibilities & Delegation (ICH E6 4.0 / 21 CFR 312.60) 6.2 Sponsor Roles, Responsibilities, and Quality Management (ICH E6 5.0) 6.3 Financial Agreements, Contracts, and Insurance
7 Chapter 7: Study Implementation & Clinical Operations
7.1 Subject Recruitment, Screening, and Enrolling Procedures 7.2 Investigational Product (IP) Receipt, Accountability, and Disposition 7.3 Protocol Compliance, Deviations, and Corrective Action Plans
8 Chapter 8: Safety Definitions & Reporting Workflows
8.1 Adverse Events, Serious Adverse Events, and SUSARs (ICH E2A) 8.2 Safety Reporting Timelines (Investigator-Sponsor-FDA-IRB) 8.3 Device-Related Safety Reporting & Unanticipated Adverse Device Effects (UADEs)
9 Chapter 9: Quality Assurance, Monitoring, and Auditing
9.1 Clinical Site Monitoring (Traditional vs. Risk-Based Monitoring) 9.2 Sponsor Audits vs. Regulatory Inspections 9.3 FDA BIMO Inspections, Form 483, and Warning Letters
10 Chapter 10: Study Closure & Final Disclosures
10.1 Close-Out Visits and Administrative Wrap-Up 10.2 Record Retention Regulations (FDA vs. ICH GCP) 10.3 Final Reporting & Registration (ClinicalTrials.gov / 42 CFR 11)
6.3 Financial Agreements, Contracts, and Insurance
Key Takeaways Explain This Topic AI
Clinical Trial Agreements (CTAs) are legally binding contracts that govern scope of work, intellectual property, publication rights, and sponsor indemnification.
Under the Stark Law and Anti-Kickback Statute (AKS), payments to investigators must reflect Fair Market Value (FMV) and cannot be based on the volume or value of referrals.
Financial Disclosure Forms (FDFs) are required under 21 CFR Part 54 to report financial arrangements, with thresholds of >$50,000 for equity and >$25,000 for other payments.
Medicare NCD 310.1 covers routine standard of care costs for qualifying trials, but research-only costs must be paid by the sponsor to avoid double-dipping.
Informed consent forms must disclose whether compensation and medical treatment are available for study-related injuries under 21 CFR 50.25(a)(6).
Last updated: July 2026
Financial Agreements, Contracts, and Insurance
Clinical trials are highly complex legal and financial undertakings. To ensure legal compliance, ethical conduct, and financial integrity, trials require formal agreements between sponsors, investigators, and clinical institutions. These agreements govern the division of intellectual property, publication rights, financial budgets, liability in the event of subject injury, and compliance with federal billing and anti-fraud regulations.
The Clinical Trial Agreement (CTA)
A Clinical Trial Agreement ( CTA ) is a legally binding contract that establishes the terms, conditions, and responsibilities of the parties involved in a clinical trial. It is typically executed as a bipartite agreement (between the sponsor/CRO and the institution) or a tripartite agreement (including the sponsor, the institution, and the Principal Investigator).
Key clauses in a standard CTA include:
Scope of Work : A detailed description of the tasks the investigator and institution are contracted to perform, which must align with the clinical trial protocol.
Intellectual Property (IP) : Provisions detailing who owns the data, results, and inventions arising from the trial. Generally, the sponsor retains ownership of all data, study results, and any new IP developed using the study drug or protocol.
Publication Rights : Provisions balancing the sponsor's commercial interests (e.g., protecting patent filings) with the investigator's academic freedom to publish the study results. Typically, sponsors are granted a review period (e.g., 30 to 60 days) to review drafts of publications and suggest modifications to protect confidential information, but cannot outright veto publication of the trial findings.
Confidentiality : Mutual agreements to protect proprietary information (such as the Investigator's Brochure and protocol details) and patient privacy (compliant with HIPAA and other data privacy regulations).
Indemnification : A critical clause where the sponsor agrees to defend and hold harmless the investigator and the institution against third-party claims, lawsuits, or liabilities arising directly from the proper conduct of the trial, administration of the study drug, or adherence to the protocol.
Termination : Terms under which either party can terminate the agreement early (e.g., safety concerns, material breach of contract, or low enrollment).
Trial Budgeting and Fair Market Value (FMV)
A clinical trial budget must be drafted and negotiated before a trial can begin. The budget outlines all costs associated with conducting the trial at the site. These include:
Per-Subject Costs : Costs directly tied to subject visits, such as laboratory assays, clinical assessments, imaging studies, and subject travel reimbursements.
Start-up Costs : One-time administrative costs, including contract negotiation fees, IRB submission fees, pharmacy set-up fees, and investigator meeting attendance.
Screen Failures : Reimbursements for subjects who consent and undergo screening procedures but fail to meet eligibility criteria.
Administrative Fees : Costs for ongoing coordination, long-term records archiving, and close-out activities.
Legal Compliance: Anti-Kickback Statute and Stark Law
When establishing clinical trial budgets and investigator payments, sponsors and sites must comply with federal healthcare fraud and abuse laws, specifically the Anti-Kickback Statute ( AKS ) and the Stark Law .
Anti-Kickback Statute : Prohibits offering, paying, soliciting, or receiving remuneration to induce referrals for items or services reimbursable under federal healthcare programs (e.g., Medicare or Medicaid).
Stark Law : Prohibits physicians from referring Medicare patients for designated health services to entities with which they have a financial relationship.
Fair Market Value (FMV) : To avoid violating these laws, investigator payments must represent the Fair Market Value for the actual services rendered. Payments cannot be based on the success of the trial, the volume of subjects enrolled, or as an inducement to prescribe the sponsor’s commercial products. Paying an investigator above FMV is considered a kickback and can lead to severe criminal and civil penalties.
Financial Disclosures and Conflict of Interest (21 CFR Part 54)
Under FDA regulations, sponsors must submit financial disclosure information to the FDA in marketing applications. This is designed to identify and manage potential conflicts of interest that could bias the trial's data.
The investigator must complete a Financial Disclosure Form ( FDF ) (Form FDA 3454 or 3455) to disclose specific financial arrangements. The thresholds for disclosure include:
Financial Arrangement Disclosure Threshold
Compensation affected by the outcome of the study Any amount (e.g., royalty payments, milestone bonuses, or stock options that vest upon FDA approval).
Significant equity interest in the sponsor Value exceeding $50,000 in a publicly traded sponsor company, or any equity interest (regardless of value) in a non-publicly traded sponsor company, held during the study and for 1 year following completion.
Proprietary interest in the product Any amount (e.g., patents, trademarks, copyrights, or licensing agreements).
Significant payments of other sorts (SPOs) Cumulative payments exceeding $25,000 in value (e.g., consulting fees, honoraria, grants, or equipment) made to the investigator or institution, excluding the costs of conducting the trial, during the study and for 1 year following completion.
Billing Compliance and Medicare NCD 310.1
Clinical sites must ensure they do not bill patient insurance or federal programs for services that are paid for by the sponsor. This is regulated by the Centers for Medicare & Medicaid Services (CMS) under National Coverage Determination ( NCD ) 310.1 (Routine Costs in Clinical Trials).
Routine Costs vs. Research-Only Costs
Routine Costs (Standard of Care) : Items and services that would typically be provided to a patient even if they were not enrolled in a clinical trial. Under NCD 310.1, Medicare will cover these costs for patients enrolled in qualifying clinical trials. Examples include routine blood draws, standard imaging scans, and management of side effects.
Research-Only Costs : Items and services required by the protocol that are not standard of care and are performed solely for research purposes (e.g., experimental drug administration, extra pharmacokinetic blood draws, or specialized safety scans). These costs must be paid for by the sponsor and cannot be billed to Medicare or the subject's insurance.
Double-Dipping
Double-dipping is the fraudulent practice of billing both the clinical trial sponsor and the subject's insurance or Medicare for the exact same medical service. To prevent billing compliance violations, sites perform a Coverage Analysis ( CA ). A CA is a systematic, item-by-item review of the protocol schedule of events to map every procedure to its correct billing source (sponsor vs. insurance).
Subject Injury Compensation
When a subject suffers a study-related injury, clear policies must govern who pays for medical treatment.
Informed Consent Disclosure : Under 21 CFR 50.25(a)(6) , the Informed Consent Form must state whether any compensation and/or medical treatments are available if injury occurs, what they consist of, or where further information may be obtained.
Sponsor Indemnification : In most commercial clinical trials, the CTA specifies that the sponsor will cover the direct costs of medical care required to treat injuries resulting from participation in the trial, provided the investigator followed the protocol and did not commit medical malpractice or negligence.